Does Revolade 25mg Tablet increase the number of platelets?

Yes, Revolade 25mg Tablet increases the number of platelets by stimulating megakaryocytes, the bone marrow cells responsible for producing platelets.

Revolade 25mg Tablet can liquefy the consistency of blood. How?

No, Revolade 25mg Tablet is not a blood thinner. It can't liquefy the consistency of the blood. This tablet raises the number of platelets in the blood. That makes blood thicker and prevents blood loss.

What food should I have to avoid while taking Revolade 25mg Tablet?

It is advised not to take dairy products and calcium-fortified juices at least 2 hours before or 4 hours after taking Revolade 25mg Tablet.

What should be monitored during the treatment with Revolade 25mg Tablet?

Blood platelet count and liver enzyme must be monitored regularly during treatment with Revolade 25mg Tablet. Your doctor must go for weekly cataracts and eye checkups for bleeding near the retina.

Who shouldn't take a 25 mg tablet of Revolade?

Revolade 25mg tablets should not be used by children younger than one year old or by those with immune system disorders such as primary thrombocytopenia (ITP). Additionally, it is not advised for those who have hepatitis C and severe aplastic anemia.

Is it okay to take a 25 mg tablet Revolade without food?

Yes, you should take the 25 mg Revolade capsules without food. Because this drug absorption can be blocked by antacids, dairy products, calcium-enriched diets, fortified drinks, and mineral and vitamin supplements (iron, calcium, magnesium, aluminum, selenium, and zinc). Therefore, please take them four hours after taking the drug or at least two hours before.

Will you be observed while using the 25 mg Revolade tablet?

Yes, you will be closely watched when taking the 25 mg Revolade tablet. Your complete blood count, heart rate, eye test, platelets, blood clotting factors, and white blood cells will all be routinely evaluated by your healthcare provider. Depending on how you react to the drug, a 25 mg substitute for Revolade can be taken into consideration.

Deal of the Day — limited-time pharmacy picks!Deal of the Day — today's spotlight pharmacy prices, refreshed daily.

Revolade 25mg Tablet

Name: Revolade 25mg Tablet
Brand: revolade
Price: 13900 INR
Availability: InStock
Rating: 4.29 (7 reviews)

Rx Required

Salt Composition: Eltrombopag Olamine

Expiry Date: 01/2028

Price on Request

Inclusive of all taxes

▼

14 Tablet

About The Product

Hepatitis C, Hepatitis Medicines, Low Red Platelet Count

Revolade 25mg Tablet is used to treat low platelet count due to chronic immune (idiopathic) thrombocytopenic purpura (ITP) or chronic hepatitis C virus (HCV) infection. It is also used to treat severe aplastic anemia. Revolade 25mg Tablet is a prescription-based anticoagulant drug used to increase low platelet count in the blood that is caused due to primary immune thrombocytopenia (ITP) or hepatitis C (HCV) infection. It is also given to patients to cure severe aplastic anemia.

Side Effects

Like other anticancer medicines, Revolade 25mg Tablet also has some common to severe side effects. These are undesired symptoms observed in the body after taking this injection. Usually, they disappear with time as the body adjusts to the medicine. These adverse effects don't need special medical attention, but if you observe them continually, talk to your medical expert. Some of them are listed below: Common side effects:

Diarrhea
Back pain
Appetite loss
Hair loss
headache and dizziness
Throat pain
Nausea & vomiting, muscle pain
Abdominal pain
Cold and cough
Upper respiratory tract infection
Severe side effects:
Urinary Tract Infection
Increased liver enzymes

How It Works

Revolade 25mg Tablet belongs to the class of thrombopoietin (TPO) receptor agonists, consisting of the active ingredient Eltrombopag. It stimulates the bone marrow cells, called megakaryocytes. It is responsible for producing platelets in the blood. Further, Revolade Tablet prevents the loss of blood and bruising.
Revolade 25mg Tablet is an anticoagulant drug belonging to the class of thrombopoietin (TPO) receptor agonists. The doctor prescribes this tablet to increase the blood platelet count caused due to chronic immune (idiopathic) thrombocytopenic purpura (ITP) or chronic hepatitis C virus (HCV) infection.
ITP is an autoimmune disorder in which our immune system starts damaging our platelets. Platelets are blood cells that help in blood clotting and protecting vessels. When there is a low count of platelets in the blood, it can cause bleeding. Revolade 25mg Tablet is also used to treat severe aplastic anemia.
It is a severe blood disorder that occurs when the bone marrow fails to produce enough new blood cells. It is advised not to take this tablet if you have liver disease, as Revolade 25mg Tablet can cause hepatotoxicity, increased liver enzymes, and bilirubin levels. It may worsen liver function.
Your doctor must go for a weekly eye checkup for bleeding near the retina. Inform your doctor if you are taking any prescribed and non-prescribed medications. These medicines can interact with Revolade 25mg Tablet and may result in some undesirable effects.
This tablet is not recommended for people under age 18. Revolade 25mg Tablet should not be given to children under age one to treat ITP.

Safety Advice

Alcohol

The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Revolade 25mg Tablet. Kindly consult your doctor for further information. The Revolade 25mg Tablet with alcohol may interact; however, this is uncertain. If you consume alcohol, let your doctor know.

Pregnancy

Revolade 25mg Tablet may be considered unsafe during pregnancy. Please consult your doctor in such a condition. Due to the possibility of reproductive damage, Revolade 25mg Tablet is not advised for use by expectant mothers. If you are pregnant, suspect, or want to become pregnant while undergoing treatment, you must let your doctor know.

Breast Feeding

Revolade 25mg Tablet is probably not safe if you're breastfeeding. Kindly consult your doctor. The Revolade 25mg Tablet's ability to transfer into breast milk is unknown. Inform your doctor if you are breastfeeding or intend to breastfeed.

Driving

It is advisable not to drive or operate heavy machinery as you may feel dizzy after taking Revolade 25mg Tablet. After taking the Revolade 25mg Tablet, it is dangerous to drive or operate heavy equipment. It can make you feel lightheaded and make it harder to focus.

Kidney

Share your medical history with your healthcare expert in case of kidney disease before taking Revolade 25mg Tablet.

Liver

Inform your doctor before starting Revolade 25mg Tablet if you have liver disease to avoid any serious side effects. Patients with serious liver conditions should use Revolade 25mg Tablets with caution. Severe liver failure requires dose adjustment. Before starting the treatment, let your doctor know if you have liver problems.

Quick Tips

Monitor your blood platelet count regularly. Taking Revolade 25mg Tablet can drop in the count.

It may take multiple weeks or several months to observe the benefits, so do not stop taking it until your doctor asks you to do so.

It is not recommended to overdose if you miss the prescribed one. Take a dose if you miss it in less than 12 hours. If 12 hours have passed, take the next day's dose.

It is advised to take Revolade 25mg Tablet at least 2 hours before or 4 hours after eating dairy products and calcium-fortified juices.

Consult with your healthcare professional before taking Revolade 25mg Tablet if you are planning to be pregnant, planning to be pregnant or breastfeeding. It is recommended to use effective birth control methods to avoid pregnancy.

This drug is not recommended for people with hypersensitivity and allergy.

FAQs

Revolade 25mg Tablet is an anticoagulant drug used to increase low platelet count in the blood, usually caused by primary immune thrombocytopenia (ITP) or hepatitis C (HCV) infection.

It is also given to patients to cure severe aplastic anemia.

Reference

Bussel, J. B., Cheng, G., Saleh, M.

N., Psaila, B., Kovaleva, L., Cheng, G., Kuter, D. J.

(2007). Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

New England Journal of Medicine, 357(22), 2237–2247. Eltrombopag Olamine (Revolade).

(n.d.). Results – ENABLE 1 and ENABLE 2 trials.

In NCBI Bookshelf. Retrieved from NCBI Bookshelf European Medicines Agency (EMA).

(n.d.). Revolade: usage, mechanism, and benefits in ITP and related conditions.

Retrieved from the EMA website - https://www.ema.europa.eu/en/medicines/human/EPAR/revolade#:~:text=Revolade%20is%20a%20medicine%20that,are%20at%20risk%20of%20bleeding. Kuter, D.

J., Bussel, J. B., Lyons, R.

M., et al. (2008).

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomized, double‑blind, placebo‑controlled trial. Blood, 111(11), 5327–5333 - https://pubmed.ncbi.nlm.nih.gov/19231632/ Medicines Information Source (MIMS HK).

(n.d.). Eltrombopag in hepatic impairment: initiating at 25 mg once daily.

Retrieved from MIMS Hong Kong - https://www.mims.com/india/drug/info/eltrombopag?mtype=generic Park, S., Brümmendorf, T. H., Fenaux, P., et al.

(2017). Eltrombopag versus placebo for low‑risk myelodysplastic syndromes with thrombocytopenia (EQoL‑MDS): Phase 1 results of a single‑blind, randomized, controlled, phase 2 superiority trial.

The Lancet Haematology, 4(1), e22–e31 - https://pubmed.ncbi.nlm.nih.gov/28162984/ Peffault de Latour, R., Bacigalupo, A., Socié, G., et al. (2022).

Eltrombopag added to immunosuppression in severe aplastic anemia. New England Journal of Medicine, 386(15), 1392–1402 - https://pubmed.ncbi.nlm.nih.gov/34986284/ Rahman, A., Ahmed, T., et al.

(2020). Investigation of the efficacy and safety of eltrombopag to correct thrombocytopenia in moderate to severe dengue patients: A randomized, controlled clinical trial. eClinicalMedicine, 25, 100457.

SmPC (RxReasoner). (n.d.).

Eltrombopag (Revolade): dosage recommendations, including 25 mg initiation for specific populations. Retrieved from RxReasoner Terazawa, S., et al.

(2012). Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: A randomized, open‑label, phase II study.

Journal of Hepatology, 56(6), 1253–1261.

Certified Content

Written By

Venika Choudhary

Medical Content Writer @ Magicine Pharma

Reviewed By

Dr. Aditya Sarin

MBBS, MD - General Medicine, DrNB - Medical Oncology | 11 Years Experience

Check Our Editorial Policy

Last updated: 18 Sept 2026 | 04:22 PM (IST)

Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only

Not a substitute for professional medical advice

Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.

Read full medical disclaimer in Terms & Conditions